ACS GCI Pharmaceutical Roundtable

ACS GCI Pharmaceutical Roundtable—Catalyzing green chemistry & engineering in the global pharmaceutical industry.

Greener Oligos

NOTE: Peptides and Oligos are now two separate teams.

This is a fast-growing area of interest for the Pharmaceutical industry and many companies have invested heavily in developing increased capabilities for peptide synthesis in-house and at contract manufacturing organizations. The synthesis of peptides and oligonucleotides is associated with the use of comparatively high volumes of solvent. RT member companies have organized around benchmarking, best practice sharing, and the identification of new synthetic methodologies in an attempt to reduce the impacts associated with these processes.

Team Leads

Michael Kopach
Eli Lilly

Team Members

Amgen, AZ, BI, Biogen, BMS, Genentech, GSK, JNJ, Lilly, Roche, Takeda, WuXi

Goal

Greening Processes externally and at member companies.

Team Folder

DMS: Oligos

Projects

 

Team Status

Updated: October 2021

Achievements

  • Perspectives article published in the Journal of Organic Chemistry in Jan 2021
  • Compiled PMI data on oligo process, review of green chem improvements
  • Presented paper at TIDES Europe Nov 2020 and TIDES USA in Sep 2021
WuXi has joined the group

Challenges

  • A new focus for the group is needed now the paper has been published (i.e. new greener oligos publication)

Activity Snapshot

  • ACS GCIPR 2020 targeted grant is wrapping up
  • Professor Pasi Virta, University of Turku, Finland, focusing on solution phase chemistry, better protecting groups, stereoselective phosphorothioate synthesis

Upcoming Projects

  • Recruit more Pharm companies/oligo CMOs to the team
  • Submit 2022 grant proposal